Open Access Green as soon as Postprint is submitted to ZB.
Improving patient prostate cancer risk assessment: Moving from static, cross mark globally-applied to dynamic, practice-specific risk calculators.
J. Biomed. Inform. 56, 87-93 (2015)
Clinical risk calculators are now widely available but have generally been implemented in a static and one-size-fits-all fashion. The objective of this study was to challenge these notions and show via a case study concerning risk-based screening for prostate cancer how calculators can be dynamically and locally tailored to improve on-site patient accuracy. Yearly data from five international prostate biopsy cohorts (3 in the US, 1 in Austria, 1 in England) were used to compare 6 methods for annual risk prediction: static use of the online US-developed Prostate Cancer Prevention Trial Risk Calculator (PCPTRC); recalibration of the PCPTRC; revision of the PCPTRC; building a new model each year using logistic regression, Bayesian prior-to-posterior updating, or random forests. All methods performed similarly with respect to discrimination, except for random forests, which were worse. All methods except for random forests greatly improved calibration over the static PCPTRC in all cohorts except for Austria, where the PCPTRC had the best calibration followed closely by recalibration. The case study shows that a simple annual recalibration of a general online risk tool for prostate cancer can improve its accuracy with respect to the local patient practice at hand.
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Prediction ; Discrimination ; Calibration ; Prostate Cancer ; Logistic Regression ; Revision; Clinical-prediction Models; Biopsy Collaborative Group; Prevention Trial; External Validation; Cardiac-surgery; Antigen Level; Performance; Mortality; Population; Disease
ISSN (print) / ISBN 1532-0464
Quellenangaben Volume: 56, Pages: 87-93
Publishing Place San Diego
Institute(s) Institute of Computational Biology (ICB)